 | • レポートコード：D0-MOR-AP0679 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、性腺機能低下症治療の世界市場について調査・分析した資料で、性腺機能低下症治療の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The Hypogonadism Treatment Market is expected to register a CAGR of 3% during the forecast period attributing to increase in the incidence of hypogonadism, a rise in awareness about the disease and its treatment options and growth of infertility rate. Moreover, high risk of hypogonadism in the geriatric population and patient pool with diabetes and obesity are also some of the key drivers in the hypogonadism treatment market. For instance, according to a report published by the National Institute of Health (NIH), in 2019 obesity is increasing worldwide and the prevalence of hypogonadism is significantly greater in males with obesity. In addition, men aged between 60-80 years have low testosterone levels by 20% and 80% than normal testosterone levels in young men. Men above 60 years have the highest prevalence of hypogonadism. Thus, countries surging the geriatric population are witnessing a high demand for therapies to treat hypogonadism, hence, driving the hypogonadism market.
Key Market Trends
In Treatment Type Segment, Testosterone Replacement Therapy is Expected to Witness a Healthy Growth in Future
Testosterone replacement therapy is expected to contribute the largest revenue considering the fact that hypogonadism is more prevalent in men. Several government initiatives and product approvals are also boosting the testosterone replacement therapy. For instance, Clarus Therapeutics, in May 2019, received the FDA approval for Jatenzo testosterone, an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. In addition, Antares Pharma received the FDA approval in 2018 for Xyosted (testosterone enanthate) Injection.
In addition, the decreasing rate of fertility is leading to the high chances of hypogonadism and promoting the revenue growth of the overall market
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the global hypogonadism treatment market throughout the forecast period. This dominance is mainly owing to increasing cases of hypogonadism with raising awareness about the hormonal disorder, increased adoption of newer highly advanced products and advanced healthcare infrastructure. As per the report published in the European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States witnessed an increase between 1.8 and 4-fold over the last two decades (1997 – 2017) which is resulting in the growth of hypogonadism market.
Competitive Landscape
The market studied is moderately competitive and there are several international companies present in this market. Some of the companies in the market are Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals, AbbVie Inc. and Merck Serono.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Risk of Hypogonadism in Geriatric Population
4.2.2 Lifestyle Issues
4.3 Market Restraints
4.3.1 Social Taboo
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Primary Hypogonadism
5.1.2 Central Hypogonadism
5.2 By Treatment Type
5.2.1 Testosterone Replacement Therapy
5.2.2 Estrogen Therapy
5.2.3 Progesterone Therapy
5.3 By Route of Administration
5.3.1 Topical Gel
5.3.2 Transdermal Patch
5.3.3 Implantable Pellet
5.3.4 Oral Tablets
5.3.5 Others
5.4 By End User
5.4.1 Hospitals
5.4.2 Speciality Clinics
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc
6.1.2 Eli Lilly and Company
6.1.3 Teva Pharmaceutical Industries Ltd
6.1.4 Endo International
6.1.5 Ferring Pharmaceuticals
6.1.6 AbbVie Inc.
6.1.7 Merck Serono
7 MARKET OPPORTUNITIES AND FUTURE TRENDS